Management Board

Dr. Simon Moroney is CEO of MorphoSys AG and one of the Company’s co-founders. Prior to co-founding MorphoSys, Dr. Moroney held positions in the Department of Pharmacology, University of Cambridge, Cambridge, UK (1991-92), as Assistant Professor in the Chemistry Department of the University of British Columbia, Vancouver, Canada (1989-1990) and as Associate in the Chemistry Department of the Eidgenössische Technische Hochschule (ETH), in Zurich, Switzerland (1986-1989), where he also held a position as Lecturer (1988-89). From 1984 to 1986 Simon Moroney was an Associate in the Harvard Medical School, Boston, USA and an employee of ImmunoGen Inc, where he worked on the first generation of anti-cancer antibody conjugates. Dr. Moroney studied chemistry in his native New Zealand, where he completed an MSc with 1st class honors in 1981 and was a Commonwealth Scholar to the University of Oxford, where he was awarded a D. Phil. in Chemistry in 1984. In 2002, Dr. Moroney received the German Cross of the Order of Merit by Dr. Johannes Rau, President of the Federal Republic of Germany, for his services to the biotechnology industry.

Dr. Schottelius joined MorphoSys from Genentech Inc., South San Francisco, where he served as the Director of Immunology, Tissue Growth & Repair Early Development and most recently as Medical Director, Immunology Development. Prior to his position at Genentech, Dr. Schottelius held science and management positions in immunology research at Berlex Biosciences, CA, USA, and Schering AG, Berlin, Germany. After medical studies in Germany, the United Kingdom and Switzerland Dr. Schottelius received his PhD and MD degrees from the Albert-Ludwigs-University, Freiburg, Germany. Subsequently he practiced medicine as a resident physician in gastroenterology at the Charité University Hospital, Berlin, Germany, and held a research fellowship from the Crohn’s & Colitis Foundation of America at the University of North Carolina at Chapel Hill before moving into the pharmaceutical industry.